| Balance sheet (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.97B | 414.00M | 865.00M | 928.00M | 1.93B | 1.73B |
| Inventory | 2.94B | 2.81B | 2.48B | 1.87B | 1.61B | 1.35B |
| Total current assets | 8.79B | 6.92B | 6.51B | 5.76B | 6.32B | 6.69B |
| Property, plant and equipment | 4.04B | 3.29B | 2.86B | 2.45B | 2.25B | 2.08B |
| Goodwill and intangibles | 25.30B | 23.77B | 20.39B | 18.82B | 18.11B | 15.87B |
| Total assets | 43.67B | 39.40B | 35.14B | 32.47B | 32.23B | 30.78B |
| Accounts payable | 1.14B | 960.00M | 942.00M | 862.00M | 794.00M | 513.00M |
| Total current liabilities | 5.44B | 6.40B | 4.93B | 3.80B | 4.27B | 3.68B |
| Long-term debt | 11.14B | 8.97B | 8.57B | 8.91B | 8.80B | 9.13B |
| Total liabilities | 19.44B | 17.63B | 15.85B | 14.90B | 15.61B | 15.45B |
| Retained earnings | 5.57B | 2.67B | 819.00M | -750.00M | -1.39B | -2.38B |
| Shareholders' equity | 24.23B | 21.77B | 19.28B | 17.57B | 16.62B | 15.33B |
| Total debt | 11.44B | 10.75B | 9.10B | 8.94B | 9.06B | 9.14B |
| Net debt | 9.47B | 10.33B | 8.24B | 8.01B | 7.14B | 7.41B |
From Boston Scientific's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.